Helix BioPharma Corp. (HBP.TO)
CAD 1.0
(5.26%)
CAD 1.0
(5.26%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -9.26 Million CAD | -47.28% |
| 2023 | -6.29 Million CAD | -3.45% |
| 2022 | -6.08 Million CAD | 23.14% |
| 2021 | -7.91 Million CAD | 12.2% |
| 2020 | -9.01 Million CAD | -19.7% |
| 2019 | -7.52 Million CAD | 13.02% |
| 2018 | -8.65 Million CAD | 14.09% |
| 2017 | -10.07 Million CAD | -4.04% |
| 2016 | -9.68 Million CAD | -10.74% |
| 2015 | -8.74 Million CAD | -0.48% |
| 2014 | -8.7 Million CAD | -454.2% |
| 2013 | -1.57 Million CAD | 91.0% |
| 2012 | -17.44 Million CAD | -53.68% |
| 2011 | -11.34 Million CAD | 21.57% |
| 2010 | -14.46 Million CAD | -2.6% |
| 2009 | -14.1 Million CAD | -102.5% |
| 2008 | -6.96 Million CAD | 9.25% |
| 2007 | -7.67 Million CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -1.83 Million CAD | -102.99% |
| 2024 Q1 | -1.25 Million CAD | 41.78% |
| 2024 Q4 | -5.27 Million CAD | -188.26% |
| 2024 Q2 | -902 Thousand CAD | 28.07% |
| 2023 Q2 | -1.18 Million CAD | 26.21% |
| 2023 Q1 | -1.61 Million CAD | -44.14% |
| 2023 FY | -6.29 Million CAD | -3.45% |
| 2023 Q4 | -2.15 Million CAD | -60.51% |
| 2023 Q3 | -1.34 Million CAD | -12.96% |
| 2022 Q4 | -1.11 Million CAD | 13.75% |
| 2022 Q3 | -1.29 Million CAD | 34.26% |
| 2022 Q2 | -1.97 Million CAD | -15.95% |
| 2022 Q1 | -1.69 Million CAD | 35.45% |
| 2022 FY | -6.08 Million CAD | 23.14% |
| 2021 Q4 | -2.63 Million CAD | -2.93% |
| 2021 FY | -7.91 Million CAD | 12.2% |
| 2021 Q3 | -2.55 Million CAD | -2.44% |
| 2021 Q2 | -2.49 Million CAD | -1004.42% |
| 2021 Q1 | -226 Thousand CAD | 89.25% |
| 2020 Q4 | -2.1 Million CAD | 16.19% |
| 2020 FY | -9.01 Million CAD | -19.7% |
| 2020 Q1 | -2.23 Million CAD | -4.88% |
| 2020 Q2 | -2.23 Million CAD | -0.04% |
| 2020 Q3 | -2.5 Million CAD | -12.26% |
| 2019 Q3 | -2.08 Million CAD | -8.38% |
| 2019 Q2 | -1.92 Million CAD | -38.17% |
| 2019 Q1 | -1.39 Million CAD | 14.14% |
| 2019 FY | -7.52 Million CAD | 13.02% |
| 2019 Q4 | -2.12 Million CAD | -2.21% |
| 2018 Q4 | -1.62 Million CAD | 24.83% |
| 2018 FY | -8.65 Million CAD | 14.09% |
| 2018 Q3 | -2.15 Million CAD | 16.15% |
| 2018 Q2 | -2.57 Million CAD | -11.35% |
| 2018 Q1 | -2.3 Million CAD | -85.23% |
| 2017 Q1 | -3.29 Million CAD | -26.22% |
| 2017 FY | -10.07 Million CAD | -4.04% |
| 2017 Q4 | -1.24 Million CAD | 57.33% |
| 2017 Q3 | -2.92 Million CAD | -11.54% |
| 2017 Q2 | -2.61 Million CAD | 20.5% |
| 2016 Q1 | -2.6 Million CAD | -22.67% |
| 2016 Q2 | -2.22 Million CAD | 14.37% |
| 2016 FY | -9.68 Million CAD | -10.74% |
| 2016 Q4 | -2.6 Million CAD | -16.11% |
| 2016 Q3 | -2.24 Million CAD | -0.81% |
| 2015 FY | -8.74 Million CAD | -0.48% |
| 2015 Q4 | -2.12 Million CAD | -16.4% |
| 2015 Q3 | -1.82 Million CAD | 31.65% |
| 2015 Q2 | -2.66 Million CAD | -25.27% |
| 2015 Q1 | -2.12 Million CAD | -17.62% |
| 2014 Q1 | -2.14 Million CAD | -11.28% |
| 2014 Q3 | -2.11 Million CAD | 19.94% |
| 2014 Q4 | -1.81 Million CAD | 14.3% |
| 2014 Q2 | -2.63 Million CAD | -23.21% |
| 2014 FY | -8.7 Million CAD | -454.2% |
| 2013 Q1 | -2.08 Million CAD | -37.81% |
| 2013 FY | -1.57 Million CAD | 91.0% |
| 2013 Q2 | 4.66 Million CAD | 324.36% |
| 2013 Q4 | -1.92 Million CAD | 13.72% |
| 2013 Q3 | -2.23 Million CAD | -147.76% |
| 2012 Q3 | -2.9 Million CAD | 69.28% |
| 2012 Q4 | -1.51 Million CAD | 48.06% |
| 2012 FY | -17.44 Million CAD | -53.68% |
| 2012 Q2 | -9.46 Million CAD | -193.4% |
| 2012 Q1 | -3.22 Million CAD | -25.98% |
| 2011 Q4 | -2.56 Million CAD | 8.6% |
| 2011 FY | -11.34 Million CAD | 21.57% |
| 2011 Q1 | -3.6 Million CAD | 0.0% |
| 2011 Q2 | -3.95 Million CAD | -9.75% |
| 2011 Q3 | -2.8 Million CAD | 29.12% |
| 2010 FY | -14.46 Million CAD | -2.6% |
| 2009 FY | -14.1 Million CAD | -102.5% |
| 2008 FY | -6.96 Million CAD | 9.25% |
| 2007 FY | -7.67 Million CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Appili Therapeutics Inc. | -3.78 Million CAD | -145.02% |
| Eupraxia Pharmaceuticals Inc. | -37.39 Million CAD | 75.224% |
| Microbix Biosystems Inc. | -39.48 Thousand CAD | -23363.263% |
| Medicenna Therapeutics Corp. | -25.46 Million CAD | 63.622% |
| Satellos Bioscience Inc. | -15.88 Million CAD | 41.696% |
| Oncolytics Biotech Inc. | -27.75 Million CAD | 66.619% |
| Sernova Corp. | -38.99 Million CAD | 76.245% |